These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23884743)

  • 1. [Standards and perspectives in the treatment of lupus nephritis].
    Anders HJ
    Dtsch Med Wochenschr; 2013 Aug; 138(31-32):1582-4. PubMed ID: 23884743
    [No Abstract]   [Full Text] [Related]  

  • 2. Connective tissue diseases: Management of lupus nephritis-new guidelines revealed.
    Ginzler E
    Nat Rev Rheumatol; 2012 Oct; 8(10):565-6. PubMed ID: 22847470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lupus nephritis: Transatlantic management recommendations compared.
    Hiepe F
    Nat Rev Rheumatol; 2012 Dec; 8(12):697-8. PubMed ID: 23147901
    [No Abstract]   [Full Text] [Related]  

  • 4. The NIH pulse cyclophosphamide regime: the end of an era?
    Karim Y; D'Cruz DP
    Lupus; 2004; 13(1):1-3. PubMed ID: 14870910
    [No Abstract]   [Full Text] [Related]  

  • 5. Overview of lupus nephritis management guidelines and perspective from Asia.
    Mok CC; Yap DY; Navarra SV; Liu ZH; Zhao MH; Lu L; Takeuchi T; Avihingsanon Y; Yu XQ; Lapid EA; Lugue-Lizardo LR; Sumethkul V; Shen N; Chen SL; Chan TM;
    Int J Rheum Dis; 2013 Dec; 16(6):625-36. PubMed ID: 24382275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Statement on the use of mycophenolate mofetil for systemic lupus erythematosus].
    Aringer M; Fischer-Betz R; Hiepe F; ;
    Z Rheumatol; 2013 Aug; 72(6):575-80. PubMed ID: 23756593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interdisciplinary consensus to management of lupus nephritis in Germany].
    de Groot K
    Z Rheumatol; 2007 Dec; 66(8):724, 726. PubMed ID: 17965864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How do lupus glomerulonephritis and its treatment affect the renal reserve?
    Martinez-Bayona A; Musso CG; de la Hoz L; Tolosa RG; Torres HG; Martinez GA
    Int Urol Nephrol; 2019 Feb; 51(2):369-370. PubMed ID: 30515736
    [No Abstract]   [Full Text] [Related]  

  • 9. How did cyclophosphamide become the drug of choice for lupus nephritis?
    Bargman JM
    Nephrol Dial Transplant; 2009 Feb; 24(2):381-4. PubMed ID: 19056783
    [No Abstract]   [Full Text] [Related]  

  • 10. Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis.
    van Tellingen A; Voskuyl AE; Vervloet MG; Bijl M; de Sévaux RG; Berger SP; Derksen RH; Berden JH;
    Neth J Med; 2012 May; 70(4):199-207. PubMed ID: 22641632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil].
    Sixdorf U; Bauer H; Märker-Hermann E
    Dtsch Med Wochenschr; 2006 Oct; 131(41):2266-9. PubMed ID: 17036267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.
    Dall'Era M; Stone D; Levesque V; Cisternas M; Wofsy D
    Arthritis Care Res (Hoboken); 2011 Mar; 63(3):351-7. PubMed ID: 21080348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lupus nephritis: guidelines for lupus nephritis--more recommendations than data?
    Rovin BH
    Nat Rev Nephrol; 2012 Nov; 8(11):620-1. PubMed ID: 23007619
    [No Abstract]   [Full Text] [Related]  

  • 14. Nephroquiz 1: cyclophosphamide or mycofenolate mofetil?
    Samadian F; Parvin M; Faraji A; Ahmadpoor P
    Iran J Kidney Dis; 2009 Apr; 3(2):112-3. PubMed ID: 19395789
    [No Abstract]   [Full Text] [Related]  

  • 15. Determinants of patient survival in systemic lupus erythematosus--focusing on lupus nephritis.
    Chan TM
    Ethn Dis; 2006; 16(2 Suppl 2):S2-66-9. PubMed ID: 16774014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten common mistakes in the management of lupus nephritis.
    Bose B; Silverman ED; Bargman JM
    Am J Kidney Dis; 2014 Apr; 63(4):667-76. PubMed ID: 24332767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study.
    Walsh M; Solomons N; Lisk L; Jayne DR
    Am J Kidney Dis; 2013 May; 61(5):710-5. PubMed ID: 23375819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.
    Ong LM; Hooi LS; Lim TO; Goh BL; Ahmad G; Ghazalli R; Teo SM; Wong HS; Tan SY; Shaariah W; Tan CC; Morad Z
    Nephrology (Carlton); 2005 Oct; 10(5):504-10. PubMed ID: 16221103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lupus-nephritis--diagnosis and treatment].
    Norby GE; Lerang K; Holdaas H; Gran JT; Strøm EH; Draganov B; Os I; Hartmann A; Gilboe IM
    Tidsskr Nor Laegeforen; 2010 Jun; 130(11):1140-4. PubMed ID: 20531500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of proliferative lupus nephritis: a changing landscape.
    Adu D
    Kidney Int; 2006 Aug; 70(4):616-8. PubMed ID: 16900218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.